信邦制药(002390) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥1,441,207,780.35, a decrease of 8.93% compared to ¥1,582,449,461.55 in the same period last year[2] - Net profit attributable to shareholders was ¥41,244,211.17, down 29.89% from ¥58,824,843.56 year-on-year[2] - Basic earnings per share decreased by 33.33% to ¥0.02 from ¥0.03 in the same period last year[2] - Operating profit for the period was CNY 61,765,904.02, compared to CNY 80,596,910.56 in the previous period[16] - The total comprehensive income for the period was CNY 53,861,041.80, down 25% from CNY 71,693,790.38 in the previous period[17] Cash Flow - The net cash flow from operating activities increased significantly by 2,059.91%, reaching ¥55,020,064.59 compared to ¥2,547,325.59 in the previous year[5] - Cash inflow from operating activities totaled CNY 1,445,098,460.85, down 6.3% from CNY 1,541,586,484.20 in the previous period[18] - Cash outflow from operating activities was CNY 1,390,078,396.26, a decrease of 9.7% compared to CNY 1,539,039,158.61 in the previous period[18] - The net cash flow from investing activities was -CNY 34,847,321.93, an improvement from -CNY 61,053,033.28 in the previous period[19] - The net cash flow from financing activities was -CNY 40,714,131.75, an improvement from -CNY 128,283,450.80 in the previous period[19] - The ending cash and cash equivalents balance was CNY 912,180,048.98, compared to CNY 543,901,118.54 in the previous period, indicating an increase[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,016,153,188.07, a slight decrease of 0.13% from ¥9,028,336,478.89 at the end of the previous year[2] - Total liabilities amounted to CNY 2,015,625,494.24, an increase from CNY 2,008,414,826.86 in the previous period[13] - Cash and cash equivalents at the end of the period were CNY 985,249,525.33, down from CNY 1,015,515,313.40 at the beginning of the period[10] - Accounts receivable increased to CNY 2,596,090,541.54 from CNY 2,534,340,405.01[10] - Inventory decreased to CNY 1,015,339,000.49 from CNY 1,060,430,088.41[11] - Non-current assets totaled CNY 3,740,887,305.68, down from CNY 3,776,245,256.87[12] Shareholder Information - The company’s total equity attributable to shareholders increased by 0.61% to ¥6,751,300,632.76 from ¥6,710,056,421.59 at the end of the previous year[2] - The number of ordinary shareholders at the end of the reporting period was 66,968[6] Investment Income and Impairment - The company reported a 100% increase in investment income to ¥101,384.14, attributed to dividends received from investment projects[5] - The company experienced a decrease in credit impairment losses, with a loss of ¥1,582,518.96 compared to a loss of ¥3,343,367.45 in the previous year[5] Return on Equity - The weighted average return on equity was 0.61%, down 0.25 percentage points from 0.86% in the previous year[2] Audit Status - The company’s first quarter report was not audited[20]